HN2001000018A - Carboxamidas de pirimidina utiles como inhibidores de isozimas pde4. - Google Patents
Carboxamidas de pirimidina utiles como inhibidores de isozimas pde4.Info
- Publication number
- HN2001000018A HN2001000018A HN2001000018A HN2001000018A HN2001000018A HN 2001000018 A HN2001000018 A HN 2001000018A HN 2001000018 A HN2001000018 A HN 2001000018A HN 2001000018 A HN2001000018 A HN 2001000018A HN 2001000018 A HN2001000018 A HN 2001000018A
- Authority
- HN
- Honduras
- Prior art keywords
- pde4
- isozimas
- carboxamids
- inhibitors
- pyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Abstract
LA PRESENTE INVENCION ESTA RELACIONADA ESENCIALMENTE CON LOS CUATRO PRODUCTOS GENICOS DE LA CUARTA FAMILIA DE PDE4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17928200P | 2000-01-31 | 2000-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
HN2001000018A true HN2001000018A (es) | 2001-09-11 |
Family
ID=22655926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HN2001000018A HN2001000018A (es) | 2000-01-31 | 2001-06-30 | Carboxamidas de pirimidina utiles como inhibidores de isozimas pde4. |
Country Status (44)
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
EP1248597B1 (en) * | 1999-12-24 | 2005-03-30 | Glaxo Group Limited | Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate |
US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
DE10110772A1 (de) * | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
YU39503A (sh) | 2000-11-22 | 2006-05-25 | F. Hoffmann-La Roche Ag. | Derivati pirimidina |
US7250518B2 (en) | 2001-01-31 | 2007-07-31 | Pfizer Inc. | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes |
ES2239203T3 (es) * | 2001-01-31 | 2005-09-16 | Pfizer Products Inc. | Derivados nicotinamida y sus mimeticos como inhibidores de isozimas pde4. |
MXPA03006887A (es) | 2001-01-31 | 2003-11-13 | Pfizer Prod Inc | Derivados biarilicos de nicotinamida de utilidad como inhibidores de isoenzimas pde4. |
EE200300362A (et) * | 2001-01-31 | 2003-12-15 | Pfizer Products Inc. | PDE4 isosüümide inhibiitoritena kasutatavad tiasolüül-, oksasolüül-, pürrolüül- ja imidasolüülhappeamiidi derivaadid |
CZ20031902A3 (cs) | 2001-01-31 | 2004-07-14 | Pfizer Products Inc. | Etherové deriváty užitečné jako inhibitory isozymů PDE4 |
CA2447618A1 (en) * | 2001-05-23 | 2002-11-28 | Tanabe Seiyaku Co., Ltd. | A composition for regenerative treatment of cartilage disease |
CN1520313A (zh) * | 2001-05-23 | 2004-08-11 | ������ҩ��ʽ���� | 一种加速骨折愈合的组合物 |
DE10142176A1 (de) * | 2001-08-29 | 2003-03-27 | Eucro Europe Contract Res Gmbh | Verwendung einer Kombination aus ß-adrenergen Agonisten und NDMA-Antagonisten |
DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
US6951869B2 (en) * | 2002-02-26 | 2005-10-04 | Schlesinger Stephen L | Use of leukotriene receptor antagonist for treatment of scarring |
JP2005529928A (ja) * | 2002-05-28 | 2005-10-06 | アルタナ ファルマ アクチエンゲゼルシャフト | 眼の病気を治療するためのロフルミラストの眼科的使用 |
DE10224888A1 (de) * | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
US20040001895A1 (en) * | 2002-06-17 | 2004-01-01 | Pfizer Inc. | Combination treatment for depression and anxiety |
JP2005539046A (ja) * | 2002-08-29 | 2005-12-22 | シプラ・リミテッド | 特異的な抗コリン作用薬、β−2アゴニスト、および副腎皮質ステロイドを含む、治療薬および組成物 |
US20040115194A1 (en) * | 2002-09-06 | 2004-06-17 | Yi Wang | Method of treatment of asthma using antibodies to complement component C5 |
US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
US7507531B2 (en) | 2002-10-17 | 2009-03-24 | Decode Genetics Chf. | Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction |
US7851486B2 (en) | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
JP2006516548A (ja) | 2002-12-30 | 2006-07-06 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | 迅速ゲル化ポリマー組成物からの薬物送達法 |
CA2820537C (en) | 2003-04-23 | 2015-10-20 | Valeritas, Inc. | Hydraulically actuated pump for fluid administration |
US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
US20050020587A1 (en) * | 2003-07-25 | 2005-01-27 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
US7132435B2 (en) * | 2003-07-25 | 2006-11-07 | Pfizer Inc. | Compounds |
GB0317484D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
GB0317498D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Compounds |
GB0317516D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
US7153870B2 (en) | 2003-07-25 | 2006-12-26 | Pfizer Inc. | Nicotinamide derivatives useful as PDE4 inhibitors |
GB0317482D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
US20050059643A1 (en) * | 2003-08-05 | 2005-03-17 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising a steroid and a betamimetic |
WO2005014825A2 (en) * | 2003-08-08 | 2005-02-17 | Arriva Pharmaceuticals, Inc. | Methods of protein production in yeast |
US20050142104A1 (en) * | 2003-11-06 | 2005-06-30 | Zeldis Jerome B. | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
JP2007511539A (ja) * | 2003-11-14 | 2007-05-10 | バクスター・インターナショナル・インコーポレイテッド | α1−抗トリプシン組成物およびこのような組成物を用いた処置方法 |
US20090042951A1 (en) * | 2004-02-20 | 2009-02-12 | Robert Danziger | Blood Pressure Reduction in Salt-Sensitive Hypertension |
JP2007528409A (ja) * | 2004-03-09 | 2007-10-11 | アリバ ファーマシューティカルズ, インコーポレイテッド | プロテアーゼインヒビターの低用量吸入による慢性閉塞性肺疾患の処置 |
US20050239842A1 (en) * | 2004-04-23 | 2005-10-27 | Zeldis Jerome B | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
PE20060272A1 (es) * | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
WO2006014425A1 (en) | 2004-07-02 | 2006-02-09 | Biovalve Technologies, Inc. | Methods and devices for delivering glp-1 and uses thereof |
SI3056492T1 (sl) | 2004-10-08 | 2022-03-31 | Abbvie Inc. | Sol meglumina in njene kristalinične oblike zdravila (delafloksacin) |
US20070105768A1 (en) * | 2004-11-10 | 2007-05-10 | Rajiv Nayar | Dry recombinant human alpha 1-antitrypsin formulation |
ATE442854T1 (de) * | 2005-03-17 | 2009-10-15 | Proyecto Biomedicina Cima Sl | Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
CN101355876B (zh) | 2005-11-09 | 2012-09-05 | 康宾纳特克斯公司 | 一种适用于眼部给药的组合物 |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
CN101460216B (zh) | 2006-03-30 | 2013-06-19 | 瓦莱里塔斯公司 | 多筒式流体递送器械 |
JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | アンジオテンシン調節による神経新生 |
EP2026813A2 (en) | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
KR20090064418A (ko) | 2006-09-08 | 2009-06-18 | 브레인셀즈 인코퍼레이션 | 4-아실아미노피리딘 유도체 포함 조합물 |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
WO2008088727A2 (en) * | 2007-01-12 | 2008-07-24 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
US8080549B2 (en) * | 2007-01-12 | 2011-12-20 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
GB0706398D0 (en) * | 2007-04-02 | 2007-05-09 | Univ Hospital Of North Staford | Improvements in and relating to copd determination |
AR066016A1 (es) * | 2007-04-11 | 2009-07-15 | Alcon Res Ltd | Uso de un inhibidor del tnf alfa junto con una antihistamina para tratar la rinitis alergica y la conjuntivitis alergica |
CA2920996A1 (en) | 2007-10-19 | 2009-04-23 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US7989465B2 (en) * | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
AU2009244897B2 (en) | 2008-04-16 | 2014-11-13 | Alexion Pharmaceuticals, Inc. | 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
EP2323693B1 (en) * | 2008-07-30 | 2017-11-08 | Nitto Denko Corporation | Drug carriers |
EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
EP2226323A1 (en) | 2009-02-27 | 2010-09-08 | Almirall, S.A. | New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives |
EP2380890A1 (en) | 2010-04-23 | 2011-10-26 | Almirall, S.A. | New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors |
EP2394998A1 (en) | 2010-05-31 | 2011-12-14 | Almirall, S.A. | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors |
ES2631603T3 (es) * | 2011-03-31 | 2017-09-01 | Maruho Co., Ltd. | Pomada con excelente estabilidad de formulación |
EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
CN102850321A (zh) * | 2011-06-28 | 2013-01-02 | 中国科学院上海药物研究所 | 芳香氧基嘧啶甲酰胺或芳香氧基吡啶甲酰胺类化合物及其制备方法、药物组合物和用途 |
EP2782579B1 (en) | 2011-11-23 | 2019-01-02 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
KR102006547B1 (ko) * | 2017-11-16 | 2019-08-01 | 서울대학교산학협력단 | 벤즈아미드 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 염증질환의 치료 또는 예방용 약학적 조성물 |
IL275764B2 (en) * | 2018-01-11 | 2023-11-01 | Emphysema Solutions Bv | Preparations and methods for treating emphysema and other forms of chronic obstructive pulmonary disease |
KR102200032B1 (ko) * | 2019-03-13 | 2021-01-08 | 전남대학교산학협력단 | 호흡기 질환의 예방 또는 치료용 조성물 |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4861891A (en) | 1988-08-31 | 1989-08-29 | Pfizer Inc. | Antidepressant N-substituted nicotinamide compounds |
TW429148B (en) * | 1995-10-27 | 2001-04-11 | Pfizer | Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases |
ID22781A (id) | 1997-04-04 | 1999-12-09 | Pfizer Prod Inc | Turunan-turunan nikotinamida |
YU39503A (sh) * | 2000-11-22 | 2006-05-25 | F. Hoffmann-La Roche Ag. | Derivati pirimidina |
-
2001
- 2001-01-30 DK DK01901334T patent/DK1252157T3/da active
- 2001-01-30 NZ NZ519726A patent/NZ519726A/en unknown
- 2001-01-30 CZ CZ20022413A patent/CZ20022413A3/cs unknown
- 2001-01-30 BR BR0107934-4A patent/BR0107934A/pt not_active IP Right Cessation
- 2001-01-30 EE EEP200200426A patent/EE200200426A/xx unknown
- 2001-01-30 SK SK1034-2002A patent/SK10342002A3/sk unknown
- 2001-01-30 WO PCT/IB2001/000125 patent/WO2001057025A1/en not_active Application Discontinuation
- 2001-01-30 HU HU0204271A patent/HUP0204271A3/hu unknown
- 2001-01-30 JP JP2001557857A patent/JP2003522165A/ja active Pending
- 2001-01-30 DE DE60103976T patent/DE60103976T2/de not_active Expired - Fee Related
- 2001-01-30 AT AT01901334T patent/ATE269860T1/de not_active IP Right Cessation
- 2001-01-30 PL PL01357555A patent/PL357555A1/xx not_active Application Discontinuation
- 2001-01-30 CN CN01804403A patent/CN1404480A/zh active Pending
- 2001-01-30 DZ DZ013406A patent/DZ3406A1/fr active
- 2001-01-30 AU AU27003/01A patent/AU2700301A/en not_active Abandoned
- 2001-01-30 EA EA200200739A patent/EA005028B1/ru not_active IP Right Cessation
- 2001-01-30 KR KR1020027009810A patent/KR20020071029A/ko not_active Application Discontinuation
- 2001-01-30 IL IL15048601A patent/IL150486A0/xx unknown
- 2001-01-30 TR TR2004/02292T patent/TR200402292T4/xx unknown
- 2001-01-30 US US10/181,417 patent/US6740655B2/en not_active Expired - Fee Related
- 2001-01-30 CA CA002396458A patent/CA2396458C/en not_active Expired - Fee Related
- 2001-01-30 ES ES01901334T patent/ES2223772T3/es not_active Expired - Lifetime
- 2001-01-30 GE GE4896A patent/GEP20043385B/en unknown
- 2001-01-30 EP EP01901334A patent/EP1252157B1/en not_active Expired - Lifetime
- 2001-01-30 PT PT01901334T patent/PT1252157E/pt unknown
- 2001-01-30 OA OA1200200230A patent/OA12170A/en unknown
- 2001-01-30 MX MXPA02007465A patent/MXPA02007465A/es active IP Right Grant
- 2001-01-30 AP APAP/P/2002/002590A patent/AP2002002590A0/en unknown
- 2001-01-31 CO CO01007018A patent/CO5271669A1/es not_active Application Discontinuation
- 2001-01-31 PA PA20018511301A patent/PA8511301A1/es unknown
- 2001-01-31 UY UY26570A patent/UY26570A1/es not_active Application Discontinuation
- 2001-01-31 GT GT200100023A patent/GT200100023A/es unknown
- 2001-01-31 AR ARP010100435A patent/AR027336A1/es not_active Application Discontinuation
- 2001-01-31 TN TNTNSN01019A patent/TNSN01019A1/fr unknown
- 2001-01-31 PE PE2001000112A patent/PE20011059A1/es not_active Application Discontinuation
- 2001-01-31 SV SV2001000298A patent/SV2001000298A/es not_active Application Discontinuation
- 2001-06-30 HN HN2001000018A patent/HN2001000018A/es unknown
-
2002
- 2002-06-24 BG BG106868A patent/BG106868A/xx unknown
- 2002-06-25 IS IS6444A patent/IS6444A/is unknown
- 2002-07-24 CR CR6714A patent/CR6714A/es not_active Application Discontinuation
- 2002-07-29 MA MA26749A patent/MA26871A1/fr unknown
- 2002-07-29 ZA ZA200206034A patent/ZA200206034B/xx unknown
- 2002-07-30 NO NO20023614A patent/NO20023614L/no not_active Application Discontinuation
-
2003
- 2003-09-10 HK HK03106472.1A patent/HK1054232A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HN2001000018A (es) | Carboxamidas de pirimidina utiles como inhibidores de isozimas pde4. | |
CR8416A (es) | 5,7- diaminopirazolo [4,3-d] pirimidinas con actividad inhibidora de la pde-5 | |
HN2004000538A (es) | "PIRIDO[ 2,3-d ] PIRIMIDINA-2,4-DIAMINAS COMO-INHIBIDORES DE PDE 2" | |
HN2003000227A (es) | Inhibidores de quinasas | |
PA8693101A1 (es) | Compuestos de isoindol-imida y composiciones que los incluyen y mètodos para su uso | |
HN2006019068A (es) | "sintesis de (r)-n-metilnaltrexona" | |
CR8051A (es) | Compuestos farmaceuticos novedosos | |
CR7182A (es) | Benzoilsufanamidas y sulfonilbenzamidinas que se usan como agentes antitumorales | |
SE0000540D0 (sv) | New compounds | |
DK1206474T3 (da) | Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer | |
EE200300361A (et) | PDE4 isosüümide inhibiitoritena kasutatavad eetriderivaadid | |
HN2001000217A (es) | Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7 | |
CU23218A3 (es) | Derivados espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa - 7 | |
HN1999000131A (es) | Derivados del acido hidroxi pipecolato hidroxamico. | |
HN2003000285A (es) | Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa | |
IS7456A (is) | Fosfat forlyf flúoróoxindóla | |
CY1109992T1 (el) | Παραγωγα του αλφα-αμιναμιδιου χρησιμα ως αντιφλεγμονωδη μεσα | |
SE9901077D0 (sv) | Novel use | |
HN2001000278A (es) | Procedimiento para la preparacion de imidazotriazininas substituidas con sulfonamida. | |
SE9801494D0 (sv) | Novel use | |
SV2003000741A (es) | Compuesto lactamico x-13170 | |
PA8492701A1 (es) | Derivados de resorcinol. | |
ATE387449T1 (de) | Pyrazolopyrimidine | |
CR8185A (es) | Pirimidinas 2- sustituidas | |
HN2001000021A (es) | Nuevos derivados de amidas heterociclicas |